In the long game you cannot expect all news to be good. As FierceBiotech writes:
It was always going to be a long shot, given how tough brain cancer is to treat and the litany of failures left tin its wake, but Tocagen, perhaps inevitably, has seen its attempt flop, leading to a review of its operations.